Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tyrosinemia: the Quebec experience

K Paradis1

  • 1Department of Pediatrics, Hôpital Sainte-Justine, University of Montréal, Que.

Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|October 1, 1996
PubMed
Summary

Tyrosinemia is a genetic liver and kidney disorder caused by reduced fumarylacetoacetate hydrolase (FAH) activity. Liver transplantation is effective, but combined liver-kidney transplants may be needed for patients with severe renal dysfunction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulsed-light inactivation of pathogenic and spoilage bacteria on cheese surface.

Journal of dairy science·2015
Same author

Analysis of patients treated with living pig tissue for evidence of infection by porcine endogenous retroviruses.

Trends in cardiovascular medicine·2001
Same author

Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients.

Transplantation·2001
Same author

[Xenotransplantation: a program for development].

Pathologie-biologie·2000
Same author

NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation.

Transplantation·2000
Same author

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

British journal of clinical pharmacology·1999

Area of Science:

  • Genetics
  • Hepatology
  • Nephrology

Background:

  • Tyrosinemia is a genetic disorder affecting the liver and kidneys due to deficient fumarylacetoacetate hydrolase (FAH) activity.
  • Succinylacetone in bodily fluids is a key diagnostic marker, particularly relevant in Quebec due to a high prevalence (1 in 1850) in the Saguenay-Lac Saint-Jean region.
  • Clinical presentations vary widely, from acute liver failure to cirrhosis and renal failure, with hepatocarcinoma occurring in about one-third of cases.

Purpose of the Study:

  • To evaluate the efficacy of liver transplantation in treating tyrosinemia.
  • To assess the impact of liver transplantation on renal function in pediatric patients with tyrosinemia.
  • To determine optimal treatment strategies for patients with significant pre-existing renal dysfunction.

Main Methods:

  • Analysis of 28 liver transplantations (including 2 combined liver-kidney) in 25 children with tyrosinemia.
  • Assessment of pre- and post-transplantation glomerular filtration rate (GFR) and renal function.
  • Review of indications for transplantation, including hepatic nodules, neurological crises, and renal failure.

Main Results:

  • An overall survival rate of 92% was achieved post-liver transplantation.
  • Pre-transplantation abnormal GFR (<80 mL/min/1.73 m2) was documented in 54% of cases, with normalization after transplantation in most.
  • Patients with severely low GFR (<55 mL/min/1.73 m2) pre-transplant exhibited persistent borderline renal function and poor growth.

Conclusions:

  • Liver transplantation is a successful treatment for tyrosinemia, significantly improving liver and renal function.
  • Combined liver-kidney transplantation should be strongly considered for pediatric tyrosinemia patients with severely impaired GFR prior to transplant.
  • Pre-transplantation renal biopsy is recommended for evaluating patients with consistently low GFR to guide treatment decisions.

Related Experiment Videos